Validation of TREK1 ion channel activators as an immunomodulatory and neuroprotective strategy in neuroinflammation

Modulation of two-pore domain potassium (K-2P) channels has emerged as a novel field of therapeutic strategies as they may regulate immune cell activation and metabolism, inflammatory signals, or barrier integrity. One of these ion channels is the TWIK-related potassium channel 1 (TREK1). In the current study, we report the identification and validation of new TREK1 activators. Firstly, we used a modified potassium ion channel assay to perform high-throughput-screening of new TREK1 activators. Dose-response studies helped to identify compounds with a high separation between effectiveness and toxicity. Inside-out patch-clamp measurements of Xenopus laevis oocytes expressing TREK1 were used for further validation of these activators regarding specificity and activity. These approaches yielded three substances, E1, B3 and A2 that robustly activate TREK1. Functionally, we demonstrated that these compounds reduce levels of adhesion molecules on primary human brain and muscle endothelial cells without affecting cell viability. Finally, we studied compound A2 via voltage-clamp recordings as this activator displayed the strongest effect on adhesion molecules. Interestingly, A2 lacked TREK1 activation in the tested neuronal cell type. Taken together, this study provides data on novel TREK1 activators that might be employed to pharmacologically modulate TREK1 activity.

Automated summary

This study identifies and validates three new activators of TREK1 channel, namely E1, B3, and A2. These compounds reduce levels of adhesion molecules on human brain and muscle endothelial cells without affecting cell viability. Among them, A2 has the strongest effect on adhesion molecules but lacks TREK1 activation in neuronal cells. This study provides new activators that might be employed to pharmacologically modulate TREK1 activity.